Summary
The dopamine hypothesis of schizophrenia and the emphasis on other neurotransmitters, most notably norepinephirne, serotonin, and acetylcholine, in the pathogenesis of depression, have focused attention away from substantial evidence implicating dopamine in affective disorders. The clinical evidence includes alterations in depressive symptoms with aging (concomitant with possible changes in dopamine metabolism), potential dopaminergic involvement in several subtypes of depression, similarities between some of the symptoms of Parkinson's disease and those of depression (including psychomotor retardation and diminished motivation), and potential dopaminergic abnormalities in seasonal mood disorder. The biochemical evidence in patients with deprission derives from studies of homovanillic acid, a dopamine metabolite, indicating diminished dopamine turnover. In addition, there is a considerable amount of pharmacologic evidence regarding the efficacy of antidepressants with dopaminergic effects in the treatment of depression. We conclude that dopamine likely contributes significantly to the pathophysiology of depression. However, the role of dopamine in this syndrome must be understood in the context of existing theories involving other neurotransmitters which may act independently, and interact with dopamine and other neurochemicals, to contribute to depression.
Similar content being viewed by others
References
Adams RD, Victor M (1989) Principles of neurology, 4th ed. McGraw Hill, New York, pp 921–967
Agid Y, Cervera P, Hirsch E, Javoy-Agid F, Lehericy S, Raisman R, Ruberg M (1989) Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord 4 [Suppl 1]: S 1126-S 144
Agren H (1980) Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. II. Suicide. Psychiatry Res 3: 225–236
Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ (1986) Interacting neurotransmitter systems. A non-experimental approach to the 5-HIAA-HVA correlation in human CSF. J Psychiatr Res 20: 175–193
Amsterdam JD, Winokur A, Lucki I, Snyder P, Harris RI, Caroff S, Rickeis K (1982) Growth hormone, prolactin, and thyrotropin responses to gonadotropin releasing hormone in depressed patients and healthy volunteers. Psychoneuroendocrinology 7: 177–184
Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE (1980) Anti-depressant treatment in Parkinson's disease. Acta Neurol Scand 62: 210–219
APA (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R). American Psychiatric Association, Washington DC
Arbisi P, Depue RA, Spoont MR, Leon A, Ainsworth B (1989) Thermoregulatory response in seasonal affective disorder. Psychiatry Res 28: 323–334
Asberg M, Bertilsson L, Martensson B, Scalia Tomba GP, Thoren P, Traskam-Bendz (1984) CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69: 201–219
Banki CM (1977) Correlation between CSF metabolites and psychomotor activity in affective disorders. J Neurochem 28: 255–257
Banki CM, Molnar G, Vojnik M (1981) Cerebrospinal fluid amine metabolites, tryptophan, and clinical parameters in depression. J Affect Disord 3: 91–99
Banki CM, Arato M, Papp Z, Kurcz M (1984) Biochemical markers in suicidal patients. Investigations with cerebrospinal fluid amine metabolites and neuroendocrine tests. J Affect Disord 6: 341–350
Barrett J, Oxman T, Gerber P (1987) Prevalence of depression and its correlates in a general medical practive. J Affect Disord 12: 167–174
Beluzzi JD, Stein L (1977) Enkephalin may mediate euphoria and drive reward. Nature 266: 556–558
Berger PA, Faull KF, Kilhowski J, Anderson PJ, Kraemer H, Davis KL, Barchas JD (1980) CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry 137: 174–180
Berrettini WH, Post RM (1984) GABA in affective illness. In: Post RM, Ballenger JC (eds) Neurobiology of mood disorders. Williams and Wilkins, Baltimore, pp 673–685
Bertler A (1961) Occurrence and localization of catecholamines in the human brain. Acta Physiol Scand 51: 97
Beskow J, Gottfries CG, Roos BE, Winblad B (1976) Determination of monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in control group. Acta Psychiatr Scand 53: 7–20
Blazer DG (1982) Symptoms and signs. In: Depression in late life. Mosby, St. Louis, p 27
Bouras N, Bridges PK (1982) Bromocriptine in depression. Curr Med Res Opin 8: 150–153
Bowers MB, Goodman E, Sim VM (1964) Some behavioral changes in man following anticholinesterase administration. J Nerv Ment Dis 138: 383–389
Bremner JD, Abrahams LM, Crupie JE, McCawley A, Proctor RC, Sathananthan GL (1984) Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. J Clin Psychiatry 45 [4, sec 2]: 56–59
Brotman AW, Falk WE, Gelenburg AJ (1987) Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1031–1040
Brown GL, Goodwin FK, Ballenger HC, Goyer PF, Major LF (1979) Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1: 131–139
Brown RG, Marsden CD, Quinn N, Wyke MA (1984) Alterations in cognitive performance and affectarousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 47: 454–465
Bunney WE, Davis JM (1965) Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry 13: 483–494
Butcher LL, Engel J (1969) Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition. Brain Res 15: 233–242
Carlsson A, Winblad B (1976) Influence of age and time interval between death and autopsy in dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 38: 271
Carlsson A (1981) Aging and brain neurotransmitters. In: Crock T, Gershon G (eds) Strategies for the development of an effective treatment for senile dementia. Mark Dowley, New Canaan Conn, pp 93–104
Charney DS, Nelson JC (1981) Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 138: 328–333
Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215: 127–134
Corrodi H, Farnebo L, Fuxe K, Hamberger B, Ungerstedt U (1972) ET-495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol 20: 195–204
Coryell W, Tsuang MT, McDaniel J (1982) Psychotic features in major depression: is mood congruence important? J Affect Disord 4: 227–236
Creese I (1989) Receptors, radioligand binding, and psychatric disorders. In: Michels R (ed) Psychiatry, vol 3, chapter 50. Lippincott, Philadelphia, pp 1–16
Davidson J, Linnoila M, Raft D, Turnball CD (1981) MAO inhibition and control of anxiety following amitriptyline therapy: a pilot study. Acta Psychiatr Neurol Scand 63: 147–152
Davis KL, Berger PA, Hollister LE, Defraites E (1978) Physostigmine in mania. Arch Gen Psychiatry 35: 119–122
Depue RA, Arbisi P, Spoont MR, Krauss S, Leon A, Ainsworth B (1989) Seasonal and mood independence of low basal prolactin secretion in premenopausal women with seasonal affective disorder. Am J Psychiatry 146: 989–995
Depue RA, Arbisi P, Krauss S, Iacono WG, Leon A, Muir R, Allen J (1990) Seasonal independence of low prolactin concentration and high spontaneous eye blink rates in unipolar and bipolar II seasonal affective disorder. Arch Gen Psychiatry 47: 356–364
Eisemann M, Ericsson U, Von Knorring L, Perris C, Perris H, Ross S (1983) Serum dopamine-beta-hydroxylase in diagnostic subgroups of depressed patients and in relation to their personality characteristics. Neuropsychobiology 9: 193–196
Elsworth JD, Glover V, Reynolds GP, Sandler M, Less AJ, Phupradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase inhibitor without the cheese effect. Psychopharmacology (Berlin) 57: 33–38
Fann WE, Lyle FA, Higginbotham W (1984) Nomifensine vs imipramine in depressed inpatients. J Clin Psychiatry 45 [4, sec 2]: 60–62
Feighner JP, Merideth CH, Claghorn JC (1984) Multicenter placebo-controlled evaluation of nomifensine treatment in depressed outpatients. J Clin Psychiatry 45 [2, sec 2]: 47–51
Ferris RM, White HL, Cooper BR, Maxwell RA, Tang FLM, Beaman OJ, Russell A (1980) Some neurochemical properties of a novel antidepressant, Bupropion hydrochloride (Wellbutrin). Drug Dev Res 1
Fibiger HC (1984) The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 11 [Suppl]: 105–107
Fielding S, Szewczak MR (1984) Pharmacology of nomifensine: a review of animal studies. J Clin Psychiatry 45 [4, sec 2]: 12–20
Friedenberg DL, Cummings JL (1989) Parkinson's disease, depression and the on-off phenomenon. Psychosomatics 30: 94–99
Gaillard JM, Nicholson AN, Pasco PA (1989) Neurotransmitter systems. In: Kryger MH, Roth T, Dement WC (eds) Principles and practice of sleep medicine. Saunders, Philadelphia, pp 208–212
Garratini S, Barreggi SR, Marc V, Calderini G, Morselli P (1974) Effects of piribedil on noradrenaline and MOPEG-SO4 levels in the rat brain. Eur J Pharmacol 28: 214–216
Garver DL, Pandey GN, Hengeveld C, Davis JM (1977) Growth hormone response and central aminergic systems in affective diseases. Psychopharmacol Bull 13: 61–63
Gelenburg AJ, Wojcik JD, Growdon JH, Sved AF, Wurtman RJ (1980) Tyrosine for the treatment of depression. Am J Psychiatry 137: 622–623
Georgia EH (1984) Double-blind comparison of the efficacy and safety of nomifensine maleate vs placebo in depressed outpatients. J Clin Psychiatry 45 [4, see 2]: 43–46
Georgotas A, McCue RE, Friedman E, Cooper C (1987 a) Prediction of response to nortriptyline and phenelzine by platelet MAO activity. Am J Psychiatry 144: 338–340
Georgotas A, McCue RE, Cooper T, Chang I, Pervez M, Welkowitz J (1987 b) Clinical predictors of response to antidepressants in elderly patients. Biol Psychiatry 22: 733–740
Gershon S, Shaw FH (1961) Psychiatric sequelae of chronic exposure to organophosphorous insecticides. Lancet i: 1371–1374
Goldman-Rakic PS, Brown RM (1982) Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Brain Res 4: 339–349
Goldstein BJ, Brauzer B, Kentsmith D, Rosenthal S, Charalampous KD (1984) Doubleblind placebo-controlled multicenter evaluation of the efficacy and safety of nomifensine in depressed outpatients. J Clin Psychiatry 45 [4, sec 2]: 52–55
Goldstein M, Battista AF, Ohmoto T, Anagnoste B, Fuxe K (1973) Tremor and involuntary movements in monkeys: Effects of L-DOPA and of a dopamine receptor stimulating agent. Science 179: 816–817
Goodnick PJ, Extein IL (1989) Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1: 119–122
Goodwin FK, Post RM, Dunner DL, Gordon EK (1973) Cerebrospinal fluid metabolites in affective illness: the probenecid technique. Am J Psychiatry 130: 73–79
Goodwin FK, Sack RL (1974) Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. In: Usdin E (ed) Neuropsychopharmacology of monoamines and their regulatory enzymes. Raven Press, New York
Gotham A, Brown RG, Marsden CD (1986) Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49: 381–389
Gottfries CG (1981) Etiological and treatment considerations in SDAT. In: Crock T, Gershon G (eds) Strategies for the development of an effective treatment for senile dementia. Mark Dowley, New Canaan Conn, pp 107–120
Gottfries CG (1982) The metabolism of some neurotransmitters in aging and dementia disorders. Gerontology 28 [Suppl 2]: 11–19
Guan XM, McBride WJ (1989) Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 23: 541–547
Gudelsky GA (1981) Tuberoinfundibular-dopaminergic neurons and the regulation of prolactin secretion. Psychoneuroendocrinology 6: 3–16
Gurland B (1976) The comparative frequency of depression in various adult age groups. J Gerontol 31: 283–292
Guze SB, Woodruff RA, Clayton PJ (1975) The significance of psychotic affective disorders. Arch Gen Psychiatry 32: 1147–1150
Halbreich U, Grunhaus L, Ben-David M (1979) Twenty-four-hour rhythm of prolactin in depressive patients. Arch Gen Psychiatry 36: 1183–1186
Hardie RT, Lees AF, Stern GM (1984) On-off fluctuations in Parkinson's disease. Brain 107: 487–506
Hornykiewicz O (1971) Recent advances in Parkinson's disease. In: McDowell FH, Markham CH (eds) Contemporary neurology series, vol 8. Davis, Philadelphia, pp 33–65
Horrobin DF, Mtabaji JP, Karmali RA (1976) Prolactin and mental illness. Postgrad Med J [Suppl 3] 52: 79–85
Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic-adrenergic hypothesis of mania and depression. Lancet ii: 6732–6735
Janowsky DS, El-Yousef MK, Davis JM, Sekerke H (1973) Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 130: 1370–1376
Janowsky DS, El-Yousef MK, Davis JM (1974) Acetylcholine and depression. Psychosom Med 36: 248–257
Janowsky DS, Risch SC, Neborsky R (1989) Strategies for studying neurotransmitter hypotheses of affective disorders. In: Michels R (ed) Psychiatry, vol 3, chapter 55. Lipincott, Philadelphia, pp 1–10
Jimerson DC (1987) Role of dopamine mechanisms in the affective disorders. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 505–511
Jimerson DC, Cutler NR, Rost RM, Rey A, Gold PW, Brown GM, Bunney WE (1984) Neuroendocrine responses to apomorphine in depressive patients and healthy control subjects. Psychiatry Res 13: 1–12
Judd LL, Risch SC, Parker DC, Janowsky DS, Segal DS, Huey LY (1982) Blunted prolactin response: a neuroendocrine abnormality manifested by depressed patients. Arch Gen Psychiatry 39: 1413–1416
Kabins D, Gershon S (1990) Potential applications for monoamine oxidase B inhibitor. Dementia 1: 323–348
Karson CN (1983) Spontaneous eye-blink rates and dopaminergic systems. Brain 106: 643–653
Kasa K, Otsuki S, Yamamoto M, Sato M, Kuroda H, Ogawa N (1982) Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 17: 877–883
Kiloh LG, Neilson M, Andrews G (1974) Response of depressed patients to methylamphetamine. Br J Psychiatry 125: 496–499
Knoll J (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 68 [Suppl 95]: 57–80
Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J (1983) CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Arch Gen Psychiatry 40: 996–1010
Kostic VS, Djuricic BM, Covickovic-Sternic N, Bumbasirevic L, Nikolic M, Mrsuljy BB (1987) Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 234: 94–96
Kuniyoshi M, Arikawa K, Miura C, Inanaga K (1989) Parkinsonism manifesting depression as the first sign. Jpn J Psychiatr Neurol 43: 37–43
Leckman JF, Cohen DJ, Shaywith BA, Caparulo BK, Heninger GR, Bowers MB (1980) CSF monoamine metabolites in child and adult psychiatric patients: a developmental perspective. Arch Gen Psychiatry 37: 677–681
Leckman JF, Weissman MM, Prusoff BA, Caruso KA, Merikangas KR, Pauls DR, Kidd KK (1984) Subtypes of depression: family study perspective. Arch Gen Psychiatry 41: 833–888
Lee TF, Mora F, Myers RD (1985) Dopamine and thermorégulation: an evaluation with special reference to dopaminergic pathways. Neurosci Biobehav Rev 9: 589–612
Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106: 257–270
Linkowski P, Brauman H, Mendlewicz J (1980) Prolactin secretion in women with unipolar and bipolar depression. Psychiatry Res 3: 265–271
Mann J, Gershon S (1980) L-deprenyl-A selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26: 877–882
Mann J, Frances A, Kaplan RD, et al (1982) The relative efficacy of L-deprenyl, a selective monoamine oxidase type B inhibitor in endogenous and nonendogenous depression. J Clin Psychopharmacol 2: 54–57
Mann J, Aarons SF, Willner PJ (1989) A controlled sty of the antidepressant efficacy and side effects of deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45–50
Marantz R, Sachar EJ, Weitzman E, Sassin J (1976) Cortisol and GH responses to D- and L-amphetamine in monkeys. Endocrinology 99: 459–465
Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34: 642–646
Mayeux R, Stern Y, Sano M, Williams JBW, Cote LJ (1988) The relationship of serotonin to depression in Parkinson's disease. Mov Disord 3: 237–244
Meltzer HY, Cho HW, Carroll BJ, Russo P (1976) Serum dopamine-beta-hydroxlase activity in the affective psychoses and schizophrenia. Arch Gen Psychiatry 33: 585–591
Meltzer HY, Kolakowska T, Fang VS, Fogg L, Robertson A, Lewine R, Strahilevitz M, Busch D (1984) Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. Arch Gen Psychiatry 41: 512–519
Mendis N, Pare CMB, Sandler M, Glover V, Stern GM (1981) Is the failure of L-deprenyl, a selective monoamine oxidase B inhibitor, to elleviate depression related to freedom from the cheese effect? Psychopharmacology 73: 87–90
Mendlewicz J, Youdim MBH (1978) Antidepressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO type B inhibitor. J Neural Transm 43: 279–286
Mendelwicz J, Youdim MBH (1983) L-deprenyl — a selective monoamine oxidase type B inhibitor in the treatment of depression: a double-blind evaluation. Br J Psychiatry 142: 508–511
Mendlewicz J, Van Cauter E, Linkowski P (1980) Current concepts. I. The 24-hour profile of prolactin in depression. Life Sci 27: 2015–2024
Mindham RHS, Marsden CD, Parkes JD (1976) Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol Med 6: 23–33
Montgomery SA, Montgomery D (1982) Pharmacological prevention of suicidal behaviour. J Affect Disord 4: 291–298
Murphy DL, Brodie HK, Goodwin FK, Bunney WE (1971) Regular induction of hypomania by L-dopa in “bipolar” manic-depressive patients. Nature 229: 135–136
Murphy DL, Aulakh CS, Garrick NA, Sunderland T (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 545–552
Narabayashi H (1985) Pharmacological treatment of Parkinson's disease — past and future. Jpn J Neuropsychopharmacol 7: 713–728
Nelson JC, Bowers MB (1978) Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 35: 1321–1328
Nissenbaum H, Quinn NP, Brown RG, Tonne B, Gotham AM, Marsden CD (1978) Mood swings associated with the “on-off” phenomenon in Parkinson's disease. Psychol Med 17: 899–904
Oreland L, Wiberg A, Asberg M, Traskam L, Sjostrand L, Thoren P, Pertilsson L, Tybring G (1981) Platelet MAP activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Res 4: 21–29
Palaniappan V, Ramachandran V, Somasaundaram O (1983) Suicidal ideation and biogenic amines in depression. Indian J Psychiatry 25: 286–292
Pare CMB, Yeung DPH, Price K, Stacey RS (1969) 5-Hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet ii: 133–135
Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK (1981) Depressed patients have decreased binding of tritiated imipramine to platelet serotonin transporter. Arch Gen Psychiatry 38: 1315–1317
Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, Bunney WE (1978) Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant réponse. Arch Gen Psychiatry 35: 609–615
Post RM, Pickar D, Ballenger JCC, Naber D, Rubinow DR (1984) Endogenous opiates in cerebrospinal fluid: relationship to mood and anxiety. In: Post RM, Ballenger JC (eds) Neurobiology of mood disorders. Williams and Wilkins, Baltimore, pp 356–368
Puig-Antich J (1979) Plasma levels of imipramine and clinical response in prepubertal major depressive disorder. J Am Acad Psychiatry 18: 616
Puzynski S, Rode A, Zaluska M (1983) Studies on biogenic amine metabolizing enzymes (DBH, COMT, MAO) and pathogenesis of affective illness. Acta Psychiatr Scand 67: 89–95
Quitkin FM, Leibowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies So (1984) L-deprenyl in atypical depressives. Arch Gen Psychiatry 41: 777–781
Randrup A, Munkvad I, Fog R, Gerlach J, Molander L, Kjellberg B, Scheel-Kruger J (1975) Mania, depression and brain dopamine. In: Essman WB, Valzelli L (eds) Current developments in psychopharmacology, vol 2. Spectrum Publications, New York, pp 206–248
Reynolds CF, Spiker DG, Hanin I, Kupfer DJ (1983) Electroencephalographic sleep, aging, and psychopathology: new data and state of the art. Biol Psychiatry 18: 139–155
Reynolds GP, Elsworth JD, Blau K (1978) Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–544
Robertson MM, Trimble MR (1982) Major tranquillisers used as antidepressants. J Affect Disord 4: 173–193
Robins AH (1976) Depression in patients with parkinsonism. Br J Psychiatry 128: 141–145
Robinson DS, Kurtz NM (1987) Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1297–1304
Robinson DS, Davis JM, Nies A (1971) Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets. Arch Gen Psychiatry 24: 536–539
Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole J (1987) Psychotic and nonnpsychotic depressions. I. Comparisons of plasma catecholamines and cotrisol measures. Psychiatry Res 20: 143–153
Roy A (1988) Plasma HVA levels in depressed patients and controls. J Affect Disord 14: 293–296
Roy A, Brockington K (1987) Plasma dopamine-beta-hydroxlase in depressed patients and controls. Neuropsychobiology 18: 57–59
Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM (1985) Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res 15: 281–292
Roy A, Agren H, Pickar D, Linnoila M, Doran AR, Cutler NR, Paul SM (1986) Reduced cerebrospinal fluid concentrations of homovanillic acid and homovanilic acid to 5-hydroxyindoleacetic acid ratio in depressed patients: relationship to suicidality and dexamethasone nonsuppression. Am J Psychiatry 143: 1539–1545
Rudorfer MV, Golden RN, Potter WZ (1984) Second-generation antidepressants. Psychiatr Clin North Am 7: 519–534
Sapru MK, Rao BSSR, Channabasavanna SM (1989) Serum dopamine-beta-hydroxylase activity in clinical subtypes of depression. Acta Psychiatr Scand 80: 474–478
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122: 509–522
Schildkraut JJ (1978) The current status of the catecholamine hypothesis of affective disorders. In: Lipton M, DiMascio A, Killam F (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1223–1234
Silberman EK, Reus VI, Jimerson DC, Lynott AM, Post RM (1981) Heterogeneity of amphetamine response in depressed patients. Am J Psychiatry 138: 1302–1307
Silverstone T (1978) Dopamine, mood and manic-depressive psychosis. In: Garattini S (ed) Depressive disorders. Schattauer, Stuttgart, pp 419–430
Silverstone T (1984) Response to bromocriptine distinguishes bipolar from unipolar depression. Lancet 21: 903–904
Sitaram N, Gillin C, Bunney WE (1984) Cholinergic and catecholaminergic receptor sensitivity in affective illness: strategy and theory. In: Post RM, Ballenger SC (eds) Neurobiology of mood disorders. Williams and Wilkins, Baltimore, pp 629–651
Sjostrom R, Roos BE (1972) 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis. Eur J Clin Pharmacol 4: 170–176
Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH (1977) Bupropion hydrochloride [(+/−) alpha-t-butylamino-3-chloropropiopenone HCl]: a novel antidepressant agent. J Pharm Pharmacol 29: 767–769
Spiker DG, Cofsky Weiss J, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi A, Soloff PH (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142: 430–436
Strandman E, Wetterberg L., Perris C, Ross SB (1978) Serum dopamine-beta-hydroxylase in affective disorders. Neuropsychobiology 4: 248–255
Stern WC, Rogers J, Fong V, Meltzer H (1979) Influence of bupropion HCl (wellbutrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. Life Sci 25: 1717–1724
Subramanyam S (1975) Role of biogenic amines in certain pathological conditions. Brain Res 87: 335–362
Sweeney D, Nelson NC, Bowers M, Maas J, Heninger G (1978) Delusional versus nondelusional depression: neurochemical differences. Lancet ii: 100–101
Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL (1987 a) L-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibitor. Arch Gen Psychiatry 44: 427–433
Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K, Cohen RM (1987 b) Cognitive effects of L-deprenyl in Alxheimer's disease. Psychopharmacology 91: 489–495
Taylor AE, Saint-Cyr JA (1990) Depression in Parkinson's disease: reconciling physiological and psychological perspectives. Neuropsychiatr Pract Opin 2: 92–98
Theohar C, Fischer-Cornelsson K, Akesson HO, Ansari J, Gerlach G, Ohman R, Ose E, Stegnik AJ (1981) Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 30: 830–842
Traskman L, Asberg M, Bertilsson L, Sjostrand L (1981) Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 38: 631–636
Tsuang MT, Faraone S (1990) The genetics of mood disorders. John Hopkins University Press, Baltimore
Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT-2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50
van Praag HM (1982) Depression, suicide, and the metabolism of serotonin in the brain. J Affect Disord 4: 275–290
van Praag HM, Korf J (1971) Retarded depression and the dopamine metabolism. Psychopharmacologia 19: 199–203
van Praag HM, Korf J, Puite J (1970) 5-Hydroxyindoleaetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature 225: 1259–1260
van Praag HM, Korf J, Schut D (1973) Cerebral monoamines and depression: an investigation with the probenecid technique. Arch Gen Psychiatry 28: 827–831
Varga E, Tringer L (1967) Clinical trial of a new type promptly acting psychoenergetic agent (phenylisopropyl methylpropinyl-HCl, E-250). Acta Med Acad Sci Hung 23: 289–295
Vogel HP (1982) Symptoms of depression in Parkinson's disease. Pharmacopsychiatry 15: 192–196
Waehrens J, Gerlach J (1981) Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in outpatients. J Affect Disord 3: 193–202
Whiteman PD, Peck AW, Fowle ASE, Smith PR (1983) Failure of bupropion to affect prolactin or growth hormone in man. J Clin Psychiatry 44 [sec 2]: 209–210
Willner P (1983) Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res Rev 6: 237–246
Young JPR, Hughes WC, Lader M (1976) A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. Br Med J 1: 1116–1118
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brown, A.S., Gershon, S. Dopamine and depression. J. Neural Transmission 91, 75–109 (1993). https://doi.org/10.1007/BF01245227
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01245227